Sepsis News and Research RSS Feed - Sepsis News and Research

Sepsis is a life-threatening illness. Your body's response to a bacterial infection usually causes it. Your immune system goes into overdrive, overwhelming normal processes in your blood. The result is that small blood clots form, blocking blood flow to vital organs. This can lead to organ failure. Babies, old people and those with weakened immune systems are most likely to get sepsis. But even healthy people can become deathly ill from it. A quick diagnosis can be crucial, because one third of people who get sepsis die from it. Sepsis is usually treated in a hospital intensive care unit (ICU). IV antibiotics and fluids may be given to try to knock out the infection and to keep blood pressure from dropping too low. Patients may also need respirators to help them breathe.
Further Reading
UCLA-led stroke study selected as one of 10 most outstanding research papers by CRF

UCLA-led stroke study selected as one of 10 most outstanding research papers by CRF

A UCLA-led study on improving stroke care was selected by the Clinical Research Forum (CRF) as one of the 10 most outstanding research papers written by teams from across the nation in 2014. The organization highlighted the papers at its fourth annual awards ceremony in Washington, D.C. on April 16. [More]
New Commission outlines current state of research into sepsis

New Commission outlines current state of research into sepsis

Leading doctors today [Monday 20 April, 2015] warn that medical and public recognition of sepsis--thought to contribute to between a third and a half of all hospital deaths--must improve if the number of deaths from this common and potentially life-threatening condition are to fall. [More]
Genetically modified Salmonella can help kill cancer cells

Genetically modified Salmonella can help kill cancer cells

A new study has demonstrated that genetically modified Salmonella can be used to kill cancer cells. The study is published in this week's issue of mBio, an American Society for Microbiology online-only, open access journal. [More]
New study describes economic consequences of using T2Candida Panel for detection of candidemia

New study describes economic consequences of using T2Candida Panel for detection of candidemia

A new study describes a model that estimates the economic consequences of using the T2Candida Panel (a novel diagnostic product that provides Candida detection) as an adjunct to the current blood culture-based diagnostic strategy in a high-risk hospital patient cohort. [More]
Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

Amgen today announced that the European Commission approved a new use of Vectibix (panitumumab) as first-line treatment in combination with FOLFIRI for the treatment of adult patients with wild-type (WT) RAS metastatic colorectal cancer (mCRC). [More]
Outpatient treatments with fewer injections produce similar results to standard treatment course

Outpatient treatments with fewer injections produce similar results to standard treatment course

Giving fewer antibiotic injections to young infants in the developing world with severe infections such as pneumonia and sepsis is just as safe and effective as the standard course of twice daily injections over the course of a week, according to new Johns Hopkins School of Public Health research conducted in Bangladesh. [More]
BP monitoring essential for early diagnosis, management of hypertensive disorders in pregnancy

BP monitoring essential for early diagnosis, management of hypertensive disorders in pregnancy

Accurate blood pressure measurement (BP) is fundamental to the early diagnosis of hypertensive disorders in pregnancy, says a review published 1 April, 2015, in The Obstetrician & Gynaecologist (TOG). [More]
Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira, Inc., a global leader in biosimilars and the world's leading provider of injectable drugs and infusion technologies, announces the availability of INFLECTRA (infliximab) in Canada, the country's first subsequent entry biologic (SEB) monoclonal antibody (mAb) therapy. [More]
Experts call for global review of sepsis guidelines

Experts call for global review of sepsis guidelines

Experts are calling for a global review of guidelines used to diagnose sepsis, after a study found one in eight patients with infections severe enough to need admission to an Intensive Care Unit in Australia and New Zealand, did not meet current criteria. [More]
Cardiovascular researchers identify MG53 protein necessary for repairing injured kidney cells

Cardiovascular researchers identify MG53 protein necessary for repairing injured kidney cells

Cardiovascular researchers at The Ohio State University Wexner Medical Center have shown that a protein known as MG53 is not only present in kidney cells, but necessary for the organ to repair itself after acute injury. Results from this animal model study are published in the journal Science Translational Medicine. [More]
New research finds old blood just as good as fresh blood

New research finds old blood just as good as fresh blood

Just like milk and many other foods, blood used for transfusions is perishable. But contrary to popular belief, new research shows that blood stored for three weeks is just as good as fresh blood - findings published today in the New England Journal of Medicine. [More]
Astute Medical hails launch of collaborative global initiative to prevent deaths from AKI by 2025

Astute Medical hails launch of collaborative global initiative to prevent deaths from AKI by 2025

Astute Medical, Inc. today hailed the launch of a collaborative global initiative calling for the elimination of preventable deaths from acute kidney injury (AKI) by 2025. The Company cited the publication of a new Commission from The Lancet and the International Society of Nephrology, along with the release of results from the 0by25 AKI "Global Snapshot" study, as key steps forward in the effort to reduce the global burden of AKI. [More]
Rehospitalizations after severe sepsis may be potentially preventable

Rehospitalizations after severe sepsis may be potentially preventable

In an analysis of about 2,600 hospitalizations for severe sepsis, readmissions within 90 days were common, and approximately 40 percent occurred for diagnoses that could potentially be prevented or treated early to avoid hospitalization, according to a study in the March 10 issue of JAMA. [More]
United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Unituxin (dinutuximab) Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. [More]
European launch of the Proxima miniature in-line blood gas analyser at ISICEM 2015

European launch of the Proxima miniature in-line blood gas analyser at ISICEM 2015

Sphere Medical, innovator in critical care monitoring and diagnostics equipment, will launch its ground-breaking in-line patient dedicated arterial blood gas analyser in Germany, Netherlands and Belgium at ISICEM 2015. [More]
Minihepcidin reverses iron overload of hemochromatosis, stops susceptibility to infections

Minihepcidin reverses iron overload of hemochromatosis, stops susceptibility to infections

Hemochromatosis (HH) is the most common genetic disorder in the western world, and yet is barely known. Only in the US 1 in 9 people carry the mutation (although not necessarily the disease). [More]
FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

Actavis plc, a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, today announced the approval of LILETTA (levonorgestrel-releasing intrauterine system) by the U.S. Food and Drug Administration for use by women to prevent pregnancy for up to three years. [More]
Trinity scientists reveal new marvel molecule that can block key process in inflammatory diseases

Trinity scientists reveal new marvel molecule that can block key process in inflammatory diseases

Scientists at Trinity College Dublin have uncovered a marvel molecule that blocks a key driver of inflammatory diseases. The finding could meet a major unmet clinical need by inspiring new non-invasive treatments for arthritis, multiple sclerosis and Muckle-Wells syndrome, among a myriad of other inflammatory diseases. [More]
UT Arlington chemist receives NIH's Academic Research Enhancement Award for protein research

UT Arlington chemist receives NIH's Academic Research Enhancement Award for protein research

A University of Texas at Arlington bio-analytical chemist exploring proteins, their structures and functions by using cutting-edge analytical instrumentation called mass spectrometry has received an Academic Research Enhancement Award from the National Institutes of Health. [More]
UMHS opens Massey Emergency Critical Care Center

UMHS opens Massey Emergency Critical Care Center

They come from highway accident scenes and nursing home beds, from factories and farm fields, from suburban homes, downtown sidewalks and small community hospitals. [More]
Advertisement
Advertisement